Patients with acute severe heart failure treated in the emergency department of Chuiyangliu Hospital from July 2019 to July 2020 were taken as the research subjects in this retrospective parallel controlled clinical study to compare the efficacy and prognosis between the standard western medicine treatment (control group: spironolactone+captopril) and integrated traditional Chinese and western medicine treatment (integrated group: spironolactone+captopril+Shengmai Decoction). The cardiac ejection function was measured by echocardiography. The results showed that the E/A and LVEF of the integrated group were higher than those of the control group, while the LVES and LVED were lower than those of the control group; the incidence of adverse reactions such as hypokalemia, cough, and hyperkalemia in the integrated group was lower than that in the control group; the QOL score in the integrated group was higher than that in the control group. This suggests that Shengmaiyin combined with western medicine has certain advantage in the treatment of acute severe heart failure, which can further improve cardiac function, enhance left ventricular ejection ability, reduce adverse reactions and improve the prognosis and quality of life of patients.
XI Tao
,
CHENG Zejun
,
XING Xinjun
,
GU Wei
. Advantages of the integrated traditional Chinese and western medicine in emergency treatment of severe heart failure and the effects on cardiac ejection ability[J]. Science & Technology Review, 2022
, 40(23)
: 30
-36
.
DOI: 10.3981/j.issn.1000-7857.2022.23.003
[1] 李丽,梁潇.美托洛尔联合厄贝沙坦氢氯噻嗪对老年重症心力衰竭患者B型脑钠肽左心室射血分数的影响[J].中国临床医生杂志, 2020, 48(2):152-155.
[2] Jean-Louis G. Optimal trial in myocardial infarction with the Angiotensin II Antagonist Losartan. The OPTIMAAL trial:Losartan or captopril after acute myocardial infarction[J]. Lancet, 2019, 360(9348):1884-1885.
[3] 张冰.胺碘酮治疗心衰合并心律失常患者的临床分析[J].中国现代药物应用, 2019, 13(19):62-63.
[4] 孙丽.胺碘酮与西地兰治疗急诊危重症伴快速心律失常的疗效比较[J].临床合理用药杂志, 2019, 12(28):45-46.
[5] 杨海涛.厄贝沙坦联合胺碘酮对慢性心衰合并心律失常心功能的影响[J].中国民康医学, 2019, 31(10):13-14.
[6] 中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管痛杂志编辑委员会.中国心力衰竭和治疗指南2018[J].中华心血管病杂志, 2018, 46(10):760-789.
[7] 许鹏,陈敏.不同NYHA心功能分级慢性心力衰竭患者心脏标志物四项、PCT、BNP水平变化及临床意义[J].海南医学, 2021, 32(19):2488-2491.
[8] 中华医学会,中华医学会杂志社,中华医学会全科医学分会,等.急性心力衰竭基层诊疗指南(实践版·2019)[J].中华全科医师杂志, 2019, 18(10):931-935.
[9] Croog S H, Levine S, Testa M A, et al. The effects of antihypertensive therapy on the quality of life[J]. New England Journal of Medicine, 1986, 314(26):1657-1664.
[10] 刘海,刘娟,丁星华,等.益气活血中药联合西医治疗老年慢性心衰患者临床疗效及对生活质量的影响[J].吉林中医药, 2017, 37(8):781-783.
[11] 张俊峰.参附注射液联合重组人脑利钠肽治疗急性失代偿性心力衰竭的临床疗效及安全性研究[J].海军医学杂志, 2018, 39(1):38-43.
[12] 邓元江,梁伟雄,刘卫英,等.生脉胶囊对慢性心力衰竭大鼠心肌细胞凋亡的影响[J].中国中医药信息杂志, 2009, 16(4):27-29.
[13] 钟耀生.应用生脉注射液对急性心肌梗死后左室容积和功能的影响[J].武汉职工医学院学报, 1998, 26(4):1-3.
[14] 肖静.生脉液对心血管系统的作用[J].中国中西医结合杂志, 1989, 9(11):700.
[15] 毛静远,王恒和,王强,等.生脉注射液对心力衰竭患者内源性洋地黄物质血清水平的影响[J].中国中医急症, 2003, 12(6):527-528.
[16] 朱阵,彭宏燕,黄婉华.参麦、生脉注射液及中药汤剂联合西药治疗急性心衰的疗效分析[J].中国实用医药, 2021, 16(12):168-169.
[17] 杨文昊,舒慧敏,刘凤阁,等.生脉注射液联合西药治疗慢性心力衰竭临床研究[J].河北医药, 2017, 39(6):913-915.
[18] 赵亚珍,熊莹,邢晨.依普利酮结合卡托普利对老年慢性心力衰竭患者心功能BNP及Nexilin的影响[J].安徽医学, 2020, 41(2):33-35.
[19] 康锐,陈珂,谢秀乐,等.射血分数与低剂量螺内酯治疗射血分数保留型心力衰竭疗效和患者预后的关系研究[J].中国全科医学, 2020, 7(3):281-288.
[20] Zhang L, Chen D, Peng M, et al. Effects of Yixintai Pills on Myocardial cell apoptosis in rats with Adriamycin-Induced heart failure[J]. The Heart Surgery Forum, 2020, 23(2):E234-E238.
[21] Butenas A, Colburn T D, Baumfalk D R, et al. Angiotensin converting enzyme inhibition improves cerebrovascular control during exercise in male rats with heart failure[J]. Respiratory Physiology&Neurobiology, 2021, 286(1985):103613-103614.
[22] 陈云,余晗俏,俞章平,等.不同剂量螺内酯对射血分数下降的心力衰竭的临床研究[J].心脑血管病防治, 2020, 20(4):91-93.
[23] 付孝清,黎昌宏,谭杰. Rho激酶抑制剂联合呋塞米及螺内酯对急性左心衰患者心功能及血清AST, LDH, CK-MB水平的影响[J].心血管康复医学杂志, 2019, 16(4):461-466.
[24] 钱芳,李林娟.不同剂量依那普利联合安体舒通治疗心力衰竭及对N末端B型利钠肽原影响研究[J].山西医药杂志, 2019, 48(10):68-71.
[25] 梁晨,赵春杰,刘雅茹.火焰原子吸收光谱法测定不同配伍生脉饮煎剂中的微量元素[J].中国中药杂志, 2009, 34(19):2526-2528.
